Given that the present treatments for ULD are only symptomatic, these results suggest that splice-modifying AOs might be a potential alternative or adjunct treatment strategy for patients holding splicing changes in the CSTB gene. This evidence concerns the gene CSTB and Unverricht-Lundborg disease.